We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
RUKOBIA (ViiV Healthcare Pty Ltd)
Product name
RUKOBIA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
191 (255 working days)
Active ingredients
fostemsavir trometamol
Registration type
NCE/NBE
Indication
RUKOBIA (extended release tablet) is indicated in combination with other antiretroviral agents for the treatment of heavily treatment-experienced adults with multidrug-resistant human immunodeficiency virus-1 (HIV-1) infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen due to resistance, intolerance or safety considerations (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).